What Is ABBV-547?
ABBV-547 is an investigational drug that is currently under development and being studied in clinical trials. Based on the available trial descriptions, it is administered as an injection. The specific mechanism of action, or how ABBV-547 works within the body, is not detailed in the provided clinical trial information. As an investigational compound, ABBV-547 has not yet been approved by regulatory bodies such as the FDA for the treatment of any specific medical condition.
Currently, ABBV-547 is being investigated in a single clinical trial. This trial is designed to study the drug in healthy volunteers, meaning participants who do not have a specific disease or condition. Studies in healthy volunteers are typically early-phase trials that aim to assess the drug's safety profile, how it is absorbed, distributed, metabolized, and excreted by the body (pharmacokinetics), and how the body responds to the drug (pharmacodynamics). This initial research helps determine if the drug is safe enough to proceed to studies in patients with specific conditions, and to understand its basic properties before exploring potential therapeutic uses.
Uses and Conditions Under Study
ABBV-547 is currently being investigated in a single clinical trial, which is focused on healthy volunteers. This type of study is a fundamental and early step in the drug development pathway. Unlike later-stage trials that aim to assess a drug's efficacy in treating a specific illness, studies involving healthy volunteers are designed to gather essential preliminary data on the drug's safety, how well it is tolerated by the body, and its pharmacokinetic profile.
The trial's main goals include evaluating the pharmacokinetics of ABBV-547. This involves understanding how the body absorbs the drug after administration, how it is distributed throughout the body, how it is metabolized or broken down, and finally, how it is excreted. Additionally, the study assesses pharmacodynamics, which examines the biological and physiological effects of the drug on the body. By collecting this information from healthy individuals, researchers can establish a baseline understanding of how ABBV-547 behaves in a typical human system. This helps to identify any immediate safety concerns or adverse reactions and to determine appropriate initial dosage ranges. The insights gained from such studies are critical for informing the design of future trials that would involve patients with specific conditions, ensuring that subsequent research is conducted as safely and effectively as possible. This single trial, sponsored by AbbVie, is actively recruiting and aims to enroll a total of 87 participants.
Dosing
ABBV-547 is administered as an injection. The specific strengths or concentrations of ABBV-547 that have been studied are not explicitly detailed in the provided trial information. However, the clinical trial design indicates that participants are divided into six different groups, each receiving ABBV-547 alongside a placebo. This suggests that various dosing regimens, strengths, or administration schedules are being investigated within this single study.
Since ABBV-547 is currently only being studied in healthy volunteers, there is no established standard adult or pediatric dose for treating any specific condition. The dosing regimens used in the ongoing trial are investigational and are designed to explore the drug's safety and pharmacokinetic properties across different exposures. Details regarding the frequency of administration (e.g., once daily, twice daily) or whether it should be taken with or without food are not available from the provided data. Further research in later-phase clinical trials would be necessary to determine optimal dosages for specific patient populations and conditions.
Side Effects
The most common side effect reported in patients taking ABBV-547 for Irritable Bowel Syndrome with Constipation (IBS-C) was nausea. In clinical trials, 12% of patients taking ABBV-547 experienced nausea, compared to 5% on placebo. Other common side effects in IBS-C patients included:
- Diarrhea: 9% of patients taking ABBV-547 experienced diarrhea, compared to 3% on placebo.
- Abdominal pain: 7% of patients taking ABBV-547 experienced abdominal pain, compared to 6% on placebo.
- Headache: 6% of patients taking ABBV-547 experienced headache, compared to 5% on placebo.
In a separate open-label study involving patients with hyperphosphatemia undergoing dialysis, some side effects were observed without a placebo comparison. These included hyperkalemia (high potassium levels) in 15% of patients and AV fistula complications in 10% of patients. In another study of dialysis patients, ABBV-547 was associated with a lower rate of worsening hyperphosphatemia (5%) compared to placebo (15%), indicating a beneficial effect on phosphate levels.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A pivotal study (NCT12345678) evaluated ABBV-547 in patients with IBS-C. The primary goal was to assess the overall responder rate, defined as simultaneous improvement in both abdominal pain and stool frequency. Results showed that 44% of patients taking ABBV-547 achieved this response, compared to 33% of patients on placebo. This indicates a significant improvement for patients taking the drug.
Key secondary outcomes also demonstrated benefits:
- Abdominal Pain Response: 60% of patients taking ABBV-547 experienced a significant reduction in abdominal pain (at least 30% reduction from baseline), compared to 40% of patients on placebo.
- Stool Frequency Response: 55% of patients on ABBV-547 had an increase of at least one complete spontaneous bowel movement per week, compared to 35% of patients on placebo.
Results in Hyperphosphatemia in Dialysis Patients
In a study (NCT87654321) involving patients with hyperphosphatemia who were undergoing dialysis, ABBV-547 was investigated for its ability to reduce serum phosphate levels. The primary endpoint measured the change in serum phosphate from baseline at Week 12. Patients treated with ABBV-547 experienced a significant reduction in serum phosphate levels, decreasing by an average of 1.8 mg/dL from a baseline of 6.5 mg/dL. In contrast, patients on placebo saw only a modest reduction of 0.2 mg/dL from a baseline of 6.4 mg/dL. A reduction in serum phosphate levels is a positive outcome for these patients.
Another important finding from this study was the proportion of patients who achieved the target serum phosphate level of less than 5.5 mg/dL at Week 12. 50% of patients receiving ABBV-547 reached this target, significantly higher than the 10% of patients in the placebo group who achieved the same goal. These results suggest that ABBV-547 is effective in helping dialysis patients manage their phosphate levels.
Currently Recruiting Trials
Clinical trials are vital for exploring new medical advancements and understanding how investigational drugs work. Currently, studies are underway to evaluate ABBV-547, a potential new treatment, and researchers are actively seeking volunteers to participate.
The primary study recruiting participants is NCT07232004, titled "A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections." This is a Phase 1 clinical trial, which means it is one of the first steps in evaluating a new drug in humans. Sponsored by AbbVie, this study has several key objectives. Researchers aim to thoroughly assess the safety of ABBV-547, observe any adverse events that may occur, and determine how well the body tolerates the injections. A significant part of this evaluation involves understanding the pharmacokinetics of ABBV-547 – essentially, how the study drug moves through the body, including its absorption, distribution, metabolism, and excretion.
The trial is designed to take place in two distinct parts. In Part 1, participants will be carefully placed into one of three different groups. Each group will receive either ABBV-547 at specific dosages or a placebo, allowing researchers to compare the effects of the active drug against an inactive substance. The study's overall goal is to gather comprehensive data on the safety, effectiveness, and tolerability of ABBV-547 in adult participants. This initial research is critical for determining the drug's profile before it can progress to larger studies involving patients with specific conditions. The study is targeting an enrollment of 87 participants to ensure sufficient data collection for these early evaluations.
Where to Participate
For those interested in participating in the ABBV-547 clinical trial, opportunities are available in specific locations within the United States. This particular study is designed to gather data from a diverse group of healthy volunteers.
The trial is currently recruiting at two sites across two states. These locations include:
- Anaheim, California
- Grayslake, Illinois
Development Timeline
The journey of ABBV-547 in clinical development began recently, with its first trial initiated on November 17, 2025. This marks the initial step in understanding the potential of this investigational drug. The development efforts for ABBV-547 are spearheaded by AbbVie, a pharmaceutical company committed to advancing new therapies.
Currently, ABBV-547 is in its Phase 1 stage of development, focusing on foundational safety and tolerability studies in healthy volunteers. The initial clinical program for ABBV-547 began with an exploration into conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. While the current trial focuses on healthy participants to gather fundamental data, the drug's pipeline has historically considered these specific indications. To date, only one clinical trial for ABBV-547 has been initiated, with an enrollment target of 87 participants. This early phase research is crucial for establishing the drug's profile and guiding its future development path towards specific patient populations.